Seer to Present at the BofA Securities 2022 Healthcare Conference

Rhea-AI Summary

Seer, a life sciences company, will participate in the BofA Securities 2022 Healthcare Conference on May 10, 2022, at 4:40 p.m. PT. The event will feature a fireside chat with Seer's management, and interested parties can access a live webcast on the investor section of Seer's website. Seer's Proteograph Product Suite offers innovative solutions for deep proteomic analysis, designed for efficiency and ease of use. This platform is intended for research purposes only and is not for diagnostic procedures.

News Market Reaction – SEER

-6.37%

-6.37% Session move

In the trading session that priced this news, SEER declined 6.37%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming BofA Securities 2022 Healthcare Conference in Las Vegas, Nevada.

Seer’s management is scheduled to participate in a fireside chat on Tuesday, May 10 at 4:40 p.m. Pacific Time / 7:40 p.m. Eastern Time. A live webcast of the virtual session will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the conference.

About Seer
Seer™ is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph™ Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.

Investor Contact
Carrie Mendivil
investor@seer.bio

Media Contact
Karen Possemato
pr@seer.bio

FAQ

When is Seer participating in the BofA Securities 2022 Healthcare Conference?

Seer will participate on May 10, 2022, at 4:40 p.m. Pacific Time.

How can I watch Seer's presentation at the Healthcare Conference?

You can watch the live webcast on the investor section of Seer's website at investor.seer.bio.

What is the focus of Seer's Proteograph Product Suite?

The Proteograph Product Suite focuses on deep, unbiased proteomic analysis.

Is Seer's product intended for diagnostic use?

No, the Proteograph Product Suite is for research use only and not intended for diagnostic procedures.

Where can I find more information about Seer?

More information can be found on Seer's official website at www.seer.bio.